LVT's DART is a patented technology platform to provide diversion and abuse-deterrant features to abused pharmaceutical products, such as opioid analgesics like Morphine and Oxycodone.
Developed initially to prevent diversion of List 1 Chemicals, such as Pseudoephedrine, Ephedrine and Phenylpropanolamine, into the manufacture of illegal methamphetamine, it was also successfully applied as a dosage form to create abuse-resistant formulations of opioids.
Pre-clinical testing has successfully shown that this technology discourages common methods of product abuse, including intentional over-dosing, nasal snorting and intravenous injection.
